2 terminated, 1 active not recruiting, 1 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
Follow AZD2811: new trials by email Literature Review of AZD2811 trials Research Report on AZD2811
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of AZD2811 + Durvalumab in ES-SCLC Durvalumab, AZD2811, Carboplatin - Small-Cell Lung Cancer | Phase 2 | Active not recruiting | AstraZeneca | 31 | 2021-02-23 | 2026-07-06 |
| AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3] AZD2811 - Small Cell Lung Cancer | Phase 2 | Terminated | Samsung Medical Center | 15 | 2017-12-01 | 2018-11-27 |
| Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. AZD2811, Azacitidine, Venetoclax - Acute Myeloid Leukaemia | Phase 1 | Terminated | AstraZeneca | 50 | 2017-07-31 | 2022-04-05 |
| A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors. AZD2811 - Advanced Solid Tumours | Phase 1 | Completed | AstraZeneca | 72 | 2015-10-28 | 2020-05-01 |
Small Cell Lung Carcinoma (3) · Leukemia, Myeloid, Acute (1)
AstraZeneca (3) · Samsung Medical Center (1)
United States (3) · South Korea (2) · Australia (1) · Poland (1) · Spain (1)
Howard A. Burris, III, M.D. (1) · Howard Burris, MD (1)